Tivicay Side Effects
Generic Name: dolutegravir
Note: This page contains side effects data for the generic drug dolutegravir. It is possible that some of the dosage forms included below may not apply to the brand name Tivicay.
It is possible that some side effects of Tivicay may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to dolutegravir: oral tablet
As well as its needed effects, dolutegravir (the active ingredient contained in Tivicay) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking dolutegravir, check with your doctor immediately:Less common
- Black, tarry stools
- blistering or peeling skin
- bloody urine
- burning, dry, or itching eyes
- chest pain
- dark urine
- decreased frequency or amount of urine
- difficulty with breathing
- discharge or excessive tearing
- general feeling of discomfort or illness
- general tiredness and weakness
- increased thirst
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- light-colored stools
- loss of appetite
- lower back or side pain
- muscle or joint aches
- nausea and vomiting
- painful or difficult urination
- rash with fever
- redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid
- severe rash
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- swelling of the face, fingers, or lower legs
- swollen glands
- troubled breathing
- unusual bleeding or bruising
- unusual tiredness or weakness
- upper right abdominal or stomach pain
- weight gain
- yellow eyes and skin
Some dolutegravir side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:Less common
- Abdominal or stomach pain or discomfort
- itching skin
- trouble sleeping
- Abnormal dreams
- Weight gain around your neck, upper back, breast, face, or waist
For Healthcare Professionals
Applies to dolutegravir: oral tablet
Discontinuation due to side effects was reported in 2% of therapy-naive patients, 2% of therapy-experienced integrase strand transfer inhibitor (INSTI)-naive patients, and 3% of therapy-experienced INSTI-experienced patients.
Very common (10% or more): Diarrhea (up to 16%), nausea (up to 15%)
Common (1% to 10%): Elevated lipase, abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting
Grade 2 and Grade 3 to 4 elevations in lipase were reported in up to 8% and up to 3% of therapy-naive patients, respectively. Elevated lipase was reported in 8% of therapy-experienced INSTI-experienced patients.
Common (1% to 10%): Hyperglycemia
Frequency not reported: Fasted lipid values increased (including cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")
Grade 2 and Grade 3 hyperglycemia were reported in up to 7% and up to 1% of therapy-naive patients, respectively. Hyperglycemia and elevated cholesterol were reported in 12% and 8% of therapy-experienced INSTI-experienced patients, respectively.
Redistribution/accumulation of body fat has been reported with antiretroviral therapy; causality has not been established.
Common (1% to 10%): Insomnia, abnormal dreams
Grade 2 and Grade 3 to 4 elevations in AST were reported in up to 3% and up to 2% of therapy-naive patients, respectively. Grade 2 and Grade 3 to 4 elevations in ALT were reported in 2% and up to 2% of therapy-naive patients, respectively. Grade 2 and Grade 3 to 4 elevations in total bilirubin were reported in up to 2% and less than 1% of therapy-naive patients, respectively. Elevated ALT and AST were reported in 8% and 6% of therapy-experienced INSTI-experienced patients, respectively.
The rates of AST and ALT abnormalities were higher patients coinfected with hepatitis B and/or C virus. ALT abnormalities (Grade 2 to 4) in hepatitis B and/or C coinfected patients compared with HIV monoinfected patients were reported in 16% versus 2% with 50 mg once a day and 8% versus 7% with 50 mg twice a day.
Liver chemistry elevations consistent with immune reconstitution syndrome were reported in some patients with hepatitis B and/or C at the start of dolutegravir (the active ingredient contained in Tivicay) therapy, especially when antihepatitis therapy was stopped.
Common (1% to 10%): Elevated AST, elevated ALT, elevated total bilirubin, hepatitis
Frequency not reported: Liver chemistry elevations consistent with immune reconstitution syndrome
Grade 2 and Grade 3 to 4 elevations in creatine kinase were reported in up to 3% and up to 4% of therapy-naive patients, respectively.
Common (1% to 10%): Elevated creatine kinase, myositis
Common (1% to 10%): Decreased total neutrophils, hematology laboratory abnormality
Grade 2 and Grade 3 to 4 reductions in total neutrophils were reported in up to 3% and 2% of therapy-naive patients, respectively. Hematology laboratory abnormality (Grade 3 to 4) was reported in 2% of therapy-experienced INSTI-experienced patients, with neutropenia (1%) reported most often.
Very common (10% or more): Headache (up to 14%)
Common (1% to 10%): Dizziness
Common (1% to 10%): Pruritus, rash (includes rash, generalized rash, macular rash, maculopapular rash, pruritic rash, drug eruption)
Common (1% to 10%): Renal impairment
Frequency not reported: Increased serum creatinine (due to inhibition of tubular secretion of creatinine)
Increased serum creatinine occurred due to inhibition of tubular secretion of creatinine without affecting renal glomerular function. Increased serum creatinine was reported within the first 4 weeks of therapy and remained stable through 24 to 48 weeks. A mean change of 0.11 mg/dL (range of -0.6 to 0.62 mg/dL) was reported after 48 weeks of therapy in therapy-naive patients.
Common (1% to 10%): Fatigue
Uncommon (0.1% to 1%): Hypersensitivity reactions (characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury)
Uncommon (0.1% to 1%): Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)
More about Tivicay (dolutegravir)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.